Shares of Pacific Biosciences of California Inc. (PACB) - Get Report were down 7.2% to $3.10  in premarket trading on Thursday, June 15. The Menlo Park, Calif.-based firm said it has priced its underwritten public offering of 15.4 million shares at $3.10 apiece. Pacific Biosciences has also given underwriters a 30-day option to buy up to an additional 2.3 million shares.

The offering would generate net proceeds of about $45.9 million after deducting the underwriting discount and estimated offering expenses, assuming no exercise of the underwriter's option to buy additional shares.

Pacific Biosciences said it plans to use the net proceeds for general corporate purposes. Part of the proceeds may also be used to acquire or invest in complementary businesses, technologies and product candidates, the company said.

AveXis Inc. (AVX) - Get Report S shares rose 4.2% to $74.11 following the announcement of an alignment with U.S. Food and Drug Administration  on the Chicago firm's good manufacturing practice commercial manufacturing process for AVXS-101.

Among the other biotech stock movers was Novavax Inc. (NVAX) - Get Report . Shares of the Gaithersburg, Md.-based firm were down 3.7% to $1.03.

Jim Cramer and the AAP team discuss the key drivers that are expected to shape the second half for Starbucks Corp. (SBUX) - Get Report . Find out what they are telling their investment club members. Get a free trial subscription to Action Alerts PLUS.

Meanwhile, over on Real Money, Brian Sozzi writes that Walmart Stores Inc. (WMT) - Get Report is "hungry, determined and moving at a speed that should frighten a grocery store like Kroger Co. (KR) - Get Report and fellow discounter Target Corp. (TGT) - Get Report ." Get his insights or analysis with a free trial subscription to Real Money.